Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

MLA

Karen A. Autio, et al. “Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 29, Aug. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....def14842a5646417300b1cb7a66160da&authtype=sso&custid=ns315887.

APA

Karen A. Autio, Manish R. Patel, Melinda Whiteside, John B. Mumm, Jeffrey R. Infante, Martin Oft, Todd M. Bauer, Patrick A. Ott, Deborah J. Wong, Nizar M. Tannir, Shubham Pant, Aung Naing, Ivan H. Chan, Peter Van Vlasselaer, Rivka R. Colen, David S. Hong, Johanna C. Bendell, Drew R. Rasco, Kyriakos P. Papadopoulos, & Gerald S. Falchook. (2016). Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(29).

Chicago

Karen A. Autio, Manish R. Patel, Melinda Whiteside, John B. Mumm, Jeffrey R. Infante, Martin Oft, Todd M. Bauer, et al. 2016. “Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34 (29). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....def14842a5646417300b1cb7a66160da&authtype=sso&custid=ns315887.